<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710433</url>
  </required_header>
  <id_info>
    <org_study_id>18_20B1</org_study_id>
    <nct_id>NCT04710433</nct_id>
  </id_info>
  <brief_title>Non-invasive Sacral Nerve Stimulation in Children and Adolescents With Chronic Constipation</brief_title>
  <official_title>Non-invasive Sacral Nerve Stimulation in Children and Adolescents With Chronic Constipation: a Case-control Study on External Neuromodulatory Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Friedrich-Alexander-Universität Erlangen-Nürnberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Friedrich-Alexander-Universität Erlangen-Nürnberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of additional neuromodulation for&#xD;
      treatment of chronic constipation in pediatric patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are selected according to the eligibility requirements. After being informed about&#xD;
      the study and potential risks of neuromodulation, all included patients and next of kin give&#xD;
      written informed consent to the study.&#xD;
&#xD;
      At baseline, patients are classified to one of the two predefined subgroups: either medical&#xD;
      and behavioral therapy is extended and optimized or neuromodulatory treatment is started with&#xD;
      non-invasive sacral nerve stimulation via single current and two external adhesive&#xD;
      electrodes. Within 12 weeks, treatment success is evaluated in routine clinical check-ups&#xD;
      (week 4/8/12) and via specialized questionnaires and bowel movement diaries. Quality of life&#xD;
      is evaluated at baseline and after 12 weeks of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms: Change in defecation frequency</measure>
    <time_frame>Baseline and 12 weeks after start of therapy</time_frame>
    <description>Defecation frequency is measured by bowel movements per week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms: Change in defecation consistency</measure>
    <time_frame>Baseline and 12 weeks after start of therapy</time_frame>
    <description>Defecation consistency is measured by the Bristol Stool Scale, which classifies stool consistency from 1 (hard consistency) to 7 (fluid consistency).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms: Change of encopresis/soiling</measure>
    <time_frame>Baseline and 12 weeks after start of therapy</time_frame>
    <description>Episodes of encopresis/soiling are evaluated per day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline and 12 weeks after start of therapy</time_frame>
    <description>The quality of life is classified via the 'Revised Children's Quality of Life Questionnaire' (KINDLR). It consists of 24 5-point Likert-scale items, covering 6 quality of life dimensions: physical well-being, emotional well-being, self-esteem, family, friends and daily functioning (school or nursery school/kindergarten). Items are partially reverse scored and linearly transformed to a 0 to 100 scale according to the manual. Higher scores indicate a better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms: Change of abdominal pain</measure>
    <time_frame>Baseline and 12 weeks after start of therapy</time_frame>
    <description>Abdominal pain is recorded in episodes per week and its intensity is evaluated via the numeric rating scale (0=no pain, 10=worst imaginable pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Constipation With Overflow</condition>
  <condition>Encopresis With Constipation and Overflow Incontinence</condition>
  <condition>Hirschprung's Disease</condition>
  <condition>Anorectal Malformations</condition>
  <arm_group>
    <arm_group_label>Non-invasive Neuromodulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of non-invasive sacral nerve stimulation for 12 weeks, at least 8 hours per day.&#xD;
Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field with a 15 Hz frequency for a duration of 210µs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).&#xD;
Medical and behavioral therapy is to be continued as started before intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical/behavioral Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receive an optimized conventional treatment for 12 weeks, including lifestyle changes, toilet training and weight-adjusted medication. Conventional medical options include oral laxative medication with polyethyleneglycol or rectal medication with saline enemas in possible combination with a stimulant laxative (glycerin or bisacodyl).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive Neuromodulation</intervention_name>
    <description>Sacral nerve stimulation via two adhesive electrodes (single current).</description>
    <arm_group_label>Non-invasive Neuromodulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical and Behavioral Therapy</intervention_name>
    <description>Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.</description>
    <arm_group_label>Medical/behavioral Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 2-17 years&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  chronic constipation according to the ROME IV criteria for more than 3 months with or&#xD;
             without encopresis/soiling&#xD;
&#xD;
          -  refractory to conventional treatment in a sufficient application (training for bowel&#xD;
             movements, lifestyle changes, pelvic floor training)&#xD;
&#xD;
          -  exclusion of metabolic, inflammatory and hormonal causes for chronic constipation&#xD;
             (such as e.g., celiac disease, cystic fibrosis, hypothyroidism)&#xD;
&#xD;
          -  in cases of underlying Hirschsprung's disease: confirmation of diagnosis via rectal&#xD;
             biopsies&#xD;
&#xD;
          -  in cases of anorectal malformation: post-surgical status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metabolic, inflammatory and hormonal causes for chronic constipation with further&#xD;
             therapeutic options&#xD;
&#xD;
          -  toxic megacolon or further emergencies, which must be treated surgically&#xD;
&#xD;
          -  fractures or substantial differences in the sacral anatomy&#xD;
&#xD;
          -  inflammatory bowel disorders&#xD;
&#xD;
          -  rectal prolapse&#xD;
&#xD;
          -  neuronal malignancies under medical and radiation therapy&#xD;
&#xD;
          -  seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonja Diez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität Erlangen-Nürnberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Besendörfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität Erlangen-Nürnberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonja Diez, MD</last_name>
    <phone>0049 09131 85 32923</phone>
    <email>sonja.diez@uk-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Friedrich-Alexander-Universität Erlangen-Nürnberg, Pediatric Surgery</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Diez, M.D.</last_name>
      <phone>0049 09131 85 32923</phone>
      <email>sonja.diez@uk-erlangen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Besendörfer M, Kohl M, Schellerer V, Carbon R, Diez S. A Pilot Study of Non-invasive Sacral Nerve Stimulation in Treatment of Constipation in Childhood and Adolescence. Front Pediatr. 2020 Apr 16;8:169. doi: 10.3389/fped.2020.00169. eCollection 2020.</citation>
    <PMID>32373563</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Friedrich-Alexander-Universität Erlangen-Nürnberg</investigator_affiliation>
    <investigator_full_name>Dr. med. Sonja Diez</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Sacral Nerve Stimulation</keyword>
  <keyword>Neuromodulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorectal Malformations</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Encopresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

